Clinical Trials
Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S1701
A Randomized Phase II trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
Status Notes
This study is open to accrual effective 8/9/18.
Research Committee(s)
Lung Cancer
Activated
08-09-2018
Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S1712
A Randomized Phase II Study of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease
Status Notes
The study is open to accrual effective 7/20/18.
Research Committee(s)
Leukemia
Activated
07-20-2018
Open
Accrual
0%
SWOG Clinical Trial Number
S1703
Randomized trial comparing overall survival of patients monitored with serum tumor marker directed disease monitoring (STMDDM) versus usual care in patients with metastatic hormone receptor positive breast cancer
Status Notes
The above-referenced study is open for participation effective July 16, 2018 at 2:00
p.m. Eastern Time.
p.m. Eastern Time.
Research Committee(s)
Cancer Care Delivery
Breast Cancer
Activated
07-16-2018
Open
Accrual
10%
SWOG Clinical Trial Number
S1702
A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis
Status Notes
This study is active for patient participation effective 3/8/18 at 2:00 p.m. Eastern.
Research Committee(s)
Myeloma
Activated
03-08-2018
Open
Phase
II
SWOG Clinical Trial Number
CTSU/EA8153
Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Status Notes
This study is open to accrual effective February 8, 2018.
Research Committee(s)
Genitourinary Cancer
Activated
02-08-2018
Open
Phase
II
Accrual
59%
SWOG Clinical Trial Number
S1400K
A PHASE II STUDY OF ABBV-399 (PROCESS II) IN PATIENTS WITH C-MET POSITIVE STAGE IV OR RECURRENT SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY)
Status Notes
Effective on 2/5/18 at 2:00 pm PST, S1400K will be activated.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study.
Research Committee(s)
Lung Cancer
Activated
02-05-2018